Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115237 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Da Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Central Laboratory, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu 215500, China; General Surgery, Can…. Hauptthemen laut MEDLINE: Breast Neoplasms, Drug Delivery Systems, Macrophages, Immunotherapy. Die Arbeit nennt 130 Literaturangaben. Gefördert von: Science and Technology Program of Suzhou, National Natural Science Foundation of China, Science and Technology Department of Zhejiang Province.
Abstract (Originalsprache)
Breast cancer (BC) remains a major global health challenge, with significant mortality despite advancements in conventional therapies. Immunotherapy, particularly through engineered macrophages, is emerging as a promising strategy for BC treatment. Macrophages play key roles in both tumor progression and immune modulation within the tumor microenvironment (TME). This review explores current engineering techniques to enhance the therapeutic potential of macrophages in BC immunotherapy. We discuss cytokine engineering, tumor-targeting receptors like chimeric antigen receptor (CAR)-macrophages, and novel drug delivery platforms, including engineered macrophages as direct drug carriers and as carriers for nanoparticles. The review also addresses the challenges in translating these strategies to clinical applications and highlights future directions for improving therapeutic outcomes in BC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Laboratory, Changshu Hospital Affiliated to Soochow University, Changshu No.1 People's Hospital, Changshu 215500, China; General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's…
- General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China.
- Department of Thyroid and Breast Surgery, Ningde Municipal Hospital of Ningde Normal University, Ningde 352100, China; Ningde Clinical Medical College of Fujian Medical University, Ningde 352100, China.
- General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China. Electronic address: wuchaoshen2019@su…
- General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China. Electronic address: hechaoqi1228@yaho…
- General Surgery, Cancer Center, Department of Breast Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou 310014, China. Electronic address: mxlmail@126.com.
Förderung
- Science and Technology Program of Suzhou
- National Natural Science Foundation of China
- Science and Technology Department of Zhejiang Province
Zitieren
APA
Qian, D., Mu, Y., Jiang, Z., Liu, H., Zhu, L., Yang, Z., Wu, C., He, C., & Meng, X. (2025). Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115237
Vancouver
Qian D, Mu Y, Jiang Z, Liu H, Zhu L, Yang Z, et al. Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115237
BibTeX
@article{Qian2025,
author = {Qian, Da and Mu, Yuxiao and Jiang, Zirong and Liu, Haotian and Zhu, Liquan and Yang, Zhuotao and Wu, Chaoshen and He, Chaoqi and Meng, Xuli},
title = {Engineered macrophages in breast Cancer: bridging targeted therapy and advanced drug delivery},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115237}
}
EUVIMED